E2F1 and sarcoma: In addition, it appears fascinating that two major transcription factors involved in oncosuppression, E2F1 (which preferentially interacts with retinoblastoma, RB) and TRP53, repress DBI and its co-expressed network of mRNAs, especially in view of the fact that DBI has procarcinogenic effects as demonstrated in models of glioblastoma [67], breast cancer, non-small cell lung cancer and sarcoma [67].